TABLE 1

Details of Patient Cohort Treated with¹⁷⁷Lu-DOTATATE

Patient no.	Sex	No. of tumors	A₁ (GBq)	A₂ (GBq)	A₃ (GBq)	A₄ (GBq)	A₅ (GBq)	A₆ (GBq)
1	Female	2	7.4^*	7.4	7.4	7.4^*	7.4	7.4
2	Female	1	7.4^*	7.4	7.4	7.4	—	—
3	Female	1	7.4^*	7.4	7.4	7.4^*	7.4	—
4	Male	3	7.4^*	7.4	6.0	—	—	—
5	Male	1	7.4^*	7.4	7.4	—	—	—
6	Male	1	7.4^*	7.4	7.4	7.4^*
7	Female	1	7.4^*	7.4	7.4	7.4^*	7.4	—
8	Female	1	7.4^*	7.4	7.4	7.4^*	7.4	7.4
9	Male	2	7.4^*	7.4	7.4^*	7.4	7.4	—
10	Male	1	7.4^*	7.4	7.4	7.4^*	—	—
11	Male	3	7.4^*	7.4	—	—	—	—
12	Male	1	7.4^*	7.4	6.0^*	7.4	7.4^*	—
13	Male	2	7.4^*	7.4^*	7.4	7.4	—	—
14	Female	2	7.4^*	7.4	6.0^*	7.4	—	—
15	Female	1	7.4^*	5.0	7.4^*	4.0	—	—
16	Male	1	7.4^*	7.4	7.4	7.4^*	—	—
17	Male	4	7.4^*	7.4	7.4^*	7.4	—	—
18	Male	1	7.4^*	7.4	7.4^*	7.4	—	—
19	Female	1	7.4^*	7.4	7.4^*	—	—	—
20	Female	3	7.4^*	7.4	7.4^*	7.4	7.4	—
21	Male	1	7.4^*	7.4	7.4^*	—	—	—
22	Female	4	7.4^*	7.4	7.4	7.4^*	—	—
23	Female	1	7.4^*	7.4	5.0^*	—	—	—
24	Male	3	7.4^*	5.0	5.0^*	—	—	—

↵* Complete dosimetric evaluation.
A_1–6 is amount of administered activity at each treatment up to 6 cycles.